A Phase 3 interventional study of Rocuronium 0.6 mg/kg intubating dose and Rocuronium 0.9 mg/kg intubating dose in Anesthesia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-17.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was conducted to determine and compare the safety and effectiveness of two neuromuscular blockers (rocuronium and vecuronium) at various doses in adults who are undergoing general elective surgery with sevoflurane anesthesia.
Study participants received an intubating dose of a neuromuscular blocker (to enable insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation). The intubating dose was followed by repeated bolus maintenance doses as needed, to maintain muscle relaxation. The time it takes to reach maximal effect of the neuromuscular blocker (onset time) after the intubating dose was measured and compared as the primary outcome.
The TOF Watch-SX (acceleration transducer) was used in the measurement of neuromuscular blocking action.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
Drug: Rocuronium 0.6 mg/kg intubating dose · Drug: Rocuronium 0.1 mg/kg maintenance dose
Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
Drug: Rocuronium 0.6 mg/kg intubating dose · Drug: Rocuronium 0.15 mg/kg maintenance dose
Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
Drug: Rocuronium 0.6 mg/kg intubating dose · Drug: Rocuronium 0.2 mg/kg maintenance
Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
Drug: Rocuronium 0.9 mg/kg intubating dose · Drug: Rocuronium 0.1 mg/kg maintenance dose
Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
Drug: Rocuronium 0.9 mg/kg intubating dose · Drug: Rocuronium 0.15 mg/kg maintenance dose
Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
Drug: Rocuronium 0.9 mg/kg intubating dose · Drug: Rocuronium 0.2 mg/kg maintenance
Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
Drug: Vecuronium 0.1 mg/kg intubating dose · Drug: Vecuronium 0.025 mg/kg maintenance dose
Drug page: Rocuronium
Rocuronium 0.6 mg/kg intubating dose
Also known as: Zemuron, Org 9426
Drug page: Rocuronium
0.9 mg/kg intubating dose of rocuronium
Also known as: Zemuron, Org 9426
Drug page: Rocuronium
Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
Also known as: Zemuron, Org 9426
Drug page: Rocuronium
Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
Also known as: Zemuron, Org 9426
Drug page: Rocuronium
Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
Also known as: Zemuron, Org 9426
Drug page: Vecuronium
Vecuronium 0.1 mg/kg intubating dose
Also known as: Norcuron
Drug page: Vecuronium
Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
Also known as: Norcuron
Onset time of intubating dose. DESCRIPTION: The time interval between the completion of injection of the study drug (rocuronium or vecuronium) and the maximal depression of first twitch--measured via TOF Watch Sx(R)-- was defined as the onset time.
Time frame: Day of Surgery, after injection of study drug until maximal depression of first twitch achieved
Number of subjects who achieved maximal block >=90% after the intubating dose. DESCRIPTION: Reaching a 90% depression of first twitch--measured via TOF Watch Sx(R)--was defined as achieving 90% block
Time frame: Day of Surgery, after injection of study drug until maximal depression of first twice achieved
Clinical duration after first maintenance dose. DESCRIPTION: The time interval between the completion of injection of study drug and return of first twitch to 25%(as measured by TOF Watch Sx(R)) was defined as the clinical duration.
Time frame: Day of Surgery, after injection of study drug until return of first twitch to 25%
No study locations are listed for this record.
The record gives a start of Feb 2003, a primary completion of Feb 2004 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rocuronium